Clinical Overview

Atrial fibrillation (AFib) is the most common sustained cardiac arrhythmia seen in clinical practice. Instead of one coordinated electrical wave sweeping out from the SA node, multiple ectopic foci in the atria — commonly clustered around the pulmonary vein openings — fire rapidly and chaotically. The atria never contract as a single unit; they quiver (“fibrillate”) too fast and too disorganized to produce an effective mechanical contraction. The AV node is bombarded with this disorganized activity and only conducts an unpredictable subset of impulses through to the ventricles, which is what produces AFib’s hallmark irregularly irregular ventricular rhythm. Ongoing AFib also drives progressive structural and electrical remodeling of the atria, part of why the arrhythmia in many patients tends to become more sustained over time — moving from paroxysmal (self-terminating) episodes toward persistent or permanent AFib.

Because the atria are not contracting effectively, AFib eliminates the normal “atrial kick” that tops off ventricular filling before each beat, and blood can pool and stagnate in the atria — particularly in the left atrial appendage — creating a substrate for clot formation. This is the mechanism behind AFib’s most feared complication: embolic stroke. AFib roughly doubles overall mortality risk, is linked to a markedly increased stroke risk, and is found in a substantial share of ischemic stroke patients. Sustained rapid ventricular rates can also lead to tachycardia-mediated cardiomyopathy and heart failure over time.

Symptoms vary widely and depend on ventricular rate and the patient’s underlying cardiac status: palpitations, fatigue, dyspnea, dizziness, lightheadedness, and chest pain are all common. Many patients, however, have no symptoms at all and are diagnosed incidentally on a monitor or routine ECG — AFib is serious whether or not it produces symptoms, since the stroke and heart-failure risks are present either way.

Risk factors overlap heavily with general cardiovascular risk: advancing age (prevalence is roughly 1% worldwide but climbs to about 9% past age 75, with a lifetime risk near 22% by age 80), hypertension, structural or valvular heart disease, heart failure, hyperthyroidism, diabetes, obesity, obstructive sleep apnea, chronic kidney disease, heavy alcohol use, prior cardiac surgery, and genetic predisposition. AFib is more common in men and in white populations, and its prevalence is projected to double or triple by 2050 as the population ages.

Interpretation Guide

Key Features:

• Rate – Atrial activity is chaotic and too fast to count as discrete beats (often described in the 300-600 bpm range); ventricular rate is commonly 100-160 bpm when untreated (“rapid ventricular response” if >100 bpm), but can run below 60 bpm in treated or AV-node-diseased patients (“slow AFib”)
• Rhythm – Irregularly irregular; no repeating R-R pattern anywhere on the strip
• P waves – Absent; replaced by fibrillatory (“f”) waves and a continuously undulating baseline with no isoelectric segment. F-waves may be fine (<0.5 mm) or coarse (>0.5 mm) in amplitude
• PR interval – Not measurable; there is no discrete P wave to measure from
• QRS complex – Usually narrow (<120 ms) unless a pre-existing bundle branch block or aberrant conduction is present. A long R-R interval followed by a short one can produce an aberrantly conducted, often right-bundle-branch-block-shaped beat (Ashman phenomenon), which can be mistaken for a ventricular ectopic
• ST segment – Not a primary diagnostic feature; a sagging ST depression can be a clue to digoxin effect in a patient already taking it, but is not specific to AFib itself
• T waves – Not a primary diagnostic feature; occasional depression or inversion in lateral leads may be seen but is nonspecific
• QT interval – Not a primary diagnostic feature of AFib
• Other findings – If AFib occurs in a patient with Wolff-Parkinson-White syndrome, conduction can proceed down the accessory pathway instead of the AV node, producing a very fast (often >200 bpm), wide-complex, irregular rhythm with beat-to-beat changes in QRS morphology — a dangerous pattern that needs urgent specialist management because of the risk of degeneration into ventricular fibrillation

The single most important recognition step is confirming true, sustained irregular irregularity across a long enough strip — brief runs of ectopy or artifact can look irregular for a few beats without being AFib. Fine fibrillatory waves are easy to miss at a glance and can make the baseline look deceptively flat or “clean,” so absence of visible P waves combined with a genuinely irregular R-R pattern is the feature to rely on, not the presence or absence of visible f-waves alone.

Key Leads

• Lead V1 – Often shows fibrillatory waves most clearly of any lead, since f-wave amplitude tends to be highest here; useful for confirming AFib when the baseline looks ambiguous in other leads.
• Lead II – The standard rhythm-strip lead for tracking the irregularly irregular R-R pattern over time.

Differential Diagnosis

• Atrial Flutter – Atrial activity is organized rather than chaotic: a single re-entrant circuit produces an evenly spaced “sawtooth” pattern at roughly 300 bpm with no isoelectric baseline between waves. Ventricular response follows a conduction ratio (fixed, such as 2:1 or 4:1, or variable via Wenckebach behavior at the AV node), which can look regular or only intermittently irregular — unlike AFib’s continuously irregularly-irregular response.
• Frequent Premature Atrial Complexes (Atrial Premature Beats) – A run of frequent PACs can look irregular over a short strip, but each beat is still preceded by a distinct, if abnormal, ectopic P wave, and the underlying rhythm between ectopic beats is regular sinus — unlike AFib’s complete, sustained absence of discernible P waves.

Treatment Brief

Confirm lead placement and obtain a longer rhythm strip before treating an irregular baseline as confirmed AFib — brief artifact or a short run of ectopy can mimic irregularity over a few beats. Correlate the rhythm with vital signs and symptoms, and notify the provider promptly for any new-onset or symptomatic AFib, especially with a rapid ventricular response, hypotension, chest pain, or altered mental status.

Management centers on three parallel goals rather than a single fix. Rate control — beta-blockers, non-dihydropyridine calcium channel blockers (diltiazem, verapamil), or digoxin — is the usual first-line approach for slowing the ventricular response without necessarily restoring sinus rhythm. Rhythm control — antiarrhythmic medications, electrical cardioversion, or catheter ablation — is used when restoring and maintaining sinus rhythm is the goal, particularly for symptomatic or recurrent AFib. Stroke prevention is assessed independently of both: stroke-risk scoring (CHA₂DS₂-VASc) determines whether anticoagulation is indicated; this is calculated by the provider, not at the bedside, with direct oral anticoagulants preferred over warfarin in most patients who need it. AFib occurring in a patient with known or suspected Wolff-Parkinson-White syndrome is a distinct, higher-acuity situation that needs urgent specialist involvement rather than routine rate-control management.